Elena Yukie Uebayashi

Dr. Elena Yukie Uebayashi

Kyoto University Hospital, Kyōto, Japan
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
TKTakayuki Kawai
Takayuki Kawai
KYKentaro Yasuchika
Kentaro Yasuchika
TITakamichi Ishii
Takamichi Ishii
HKHokahiro Katayama
Hokahiro Katayama
EUElena Yukie Uebayashi
Elena Yukie Uebayashi
SUShinji Uemoto
Shinji Uemoto
Purpose: Keratin 19 (K19) is a known marker of poor prognosis and invasion in human hepatocellular carcinoma (HCC). However, the relationship between K19 and cancer stem cells (CSCs) is unclear. Here, we determined whether K19 can be used as a new CSC marker and therapeutic target in HCC. Experimental Design: HCC cell lines were transfected with a K19 promoter–driven enhanced green fluorescence protein gene. CSC characteristics, epithelial–mesenchymal transition (EMT), and TGFb/Smad signaling were examined in FACS-isolated K19+/K19− cells. K19 and TGFb receptor 1 (TGFbR1) expression in 166 consecutive human HCC surgical specimens was examined immunohistochemically. Results: FACS-isolated single K19+ cells showed self-renewal and differentiation into K19− cells, whereas single K19− cells did not produce K19+ cells. K19+ cells displayed high proliferation capacity and 5-fluorouracil resistance in vitro. Xenotransplantation into immunodeficient mice revealed that K19+ cells reproduced, differentiated into K19− cells, and generated large tumors at a high frequency in vivo. K19+ cells were found to be involved in EMT and the activation of TGFb/Smad signaling, and these properties were suppressed by K19 knockdown or treatment with a TGFbR1 inhibitor. The TGFbR1 inhibitor also showed high therapeutic effect against K19+ tumor in the mouse xenograft model. Immunohistochemistry of HCC specimens showed that compared with K19− patients, K19+ patients had significantly poorer recurrence-free survival and higher tumor TGFbR1 expression. Conclusions: K19 is a new CSC marker associated with EMT and TGFb/Smad signaling, and it would thus be a good therapeutic target for TGFbR1 inhibition. Clin Cancer Res; 21(13); 3081–91. ©2015 AACR.

11 September 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DMDaisuke Morioka
Daisuke Morioka
MKMureo Kasahara
Mureo Kasahara
YTYasutsugu Takada
Yasutsugu Takada
JCJose Pablo Garbanzo Corrales
Jose Pablo Garbanzo Corrales
AYAtsushi Yoshizawa
Atsushi Yoshizawa
KTKoichi Tanaka
Koichi Tanaka
Forty-six pediatric patients who underwent living donor liver transplantation (LDLT) using parental liver grafts for inheritable metabolic disorders (IMD) were evaluated to determine the outcomes of the surgery, decisive factors for post-transplant patient survival and the impact of using donors who were heterozygous for the particular disorder. Disorders included Wilson disease (WD, n = 21), ornithine transcarbamylase deficiency (OTCD, n = 6), tyrosinemia type I (TTI, n = 6), glycogen storage disease (GSD, n = 4), propionic acidemia (PPA, n = 3), methylmalonic acidemia (MMA, n = 2), Crigler-Najjar syndrome type I (CNSI, n = 2), bile acid synthetic defect (BASD, n = 1) and erythropoietic protoporphyria (EPP, n = 1). The post-transplant cumulative patient survival rates were 86.8 and 81.2% at 1 and 5 years, respectively. Post-transplant patient survival and recovery of the growth retardation were significantly better in the liver-oriented diseases (WD, OTCD, TTI, CNSI and BASD) than in the non-liver-oriented diseases (GSD, PPA, MMA and EPP) and pre-transplant growth retardation disadvantageously affected post-transplant outcomes. Although 40 of 46 donors were considered heterozygous for each disorder, neither mortality nor morbidity related to the heterozygosis has been observed. LDLT using parental donors can be recommended as an effective treatment for pediatric patients with IMD. In the non-liver-oriented diseases, however, satisfactory outcomes were not obtained by hepatic replacement alone.

26 July 2016 in Scientific Reports
Verified
Journal Article
Open access
TKTakayuki Kawai
Takayuki Kawai
KYKentaro Yasuchika
Kentaro Yasuchika
TITakamichi Ishii
Takamichi Ishii
YMYuya Miyauchi
Yuya Miyauchi
HKHidenobu Kojima
Hidenobu Kojima
SUShinji Uemoto
Shinji Uemoto
The current lack of cancer stem cell (CSC) markers that are easily evaluated by blood samples prevents the establishment of new therapeutic strategies in hepatocellular carcinoma (HCC). Herein, we examined whether sex determining region Y-box 9 (SOX9) represents a new CSC marker and whether osteopontin (OPN) can be used as a surrogate marker of SOX9 in HCC. In HCC cell lines transfected with a SOX9 promoter-driven enhanced green fluorescence protein gene, FACS-isolated SOX9+ cells were capable of self-renewal and differentiation into SOX9− cells and displayed high proliferation capacity in vitro. Xenotransplantation experiments revealed that SOX9+ cells reproduced, differentiated into SOX9− cells and generated tumors at a high frequency in vivo. Moreover, SOX9+ cells were found to be involved in epithelial-mesenchymal transition (EMT) and activation of TGFb/Smad signaling. Gain/loss of function experiments showed that SOX9 regulates Wnt/beta-catenin signaling, including cyclin D1 and OPN. Immunohistochemistry of 166 HCC surgical specimens and serum OPN measurements showed that compared to SOX9− patients, SOX9+ patients had significantly poorer recurrence-free survival, stronger venous invasion and higher serum OPN levels. In conclusion, SOX9 is a novel HCC-CSC marker regulating the Wnt/beta-catenin pathway and its downstream target, OPN. OPN is a useful surrogate marker of SOX9 in HCC.

27 January 2009 in Transplantation
Verified
Journal Article
Closed access
EUElena Yukie Uebayashi
Elena Yukie Uebayashi
YTYasutsugu Takada
Yasutsugu Takada
FOFumitaka Oike
Fumitaka Oike
SSSeisuke Sakamoto
Seisuke Sakamoto
KOKohei Ogawa
Kohei Ogawa
SUShinji Uemoto
Shinji Uemoto
Background. Long-term outcomes after living donor liver transplantation (LDLT) in Wilson’s disease (WD) with heterozygous donors for WD gene are unknown. Methods. LDLT was performed for 32 patients with WD (15 men, 17 women; mean age 16 years; range, 6–40 years) at Kyoto University Hospital from 1992 to 2006. The mean follow-up time from LDLT was 6.7±4.0 years (0.04–15.0 years). Donors were mainly parents (90.6%), who were obligatory carriers of the WD mutation. The present study examined retrospectively the copper metabolism, recurrence of WD, survival rate, and neurologic outcomes after LDLT. Results. Mean ceruloplasmin at the time of LDLT was 9.7±7.3 mg/dL and increased to 22.3±5.3 mg/dL (normal, 18–37 mg/dL). Urinary copper decreased from 2704±901 to 73.7±5.2 μg/day (normal, <50 μg/day). Serum copper improved from 72.9±33.9 to 81.0±14.9 mg/dL (normal, 78–131 mg/dL). Although six patients died and two received retransplantation, the remaining 24 remain alive without recurrence, with overall survival rates of 90.6%, 83.7%, and 79.9% at 1, 5, and 10 years, respectively. Patients with chronic liver failure had a poorer prognosis (P<0.05). Conclusion. Use of liver grafts from heterozygous donors has been considered safe. Good improvements in copper metabolism were obtained without evidence of recurrence in long-term follow-up. Neuropsychologic presentations of WD improved or remained unchanged. Indications for liver transplantation in patients with WD with neurologic symptoms must be considered carefully based on the stage of neurologic damage and its irreversibility.

16 January 2018 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
HKHidenobu Kojima
Hidenobu Kojima
KYKentaro Yasuchika
Kentaro Yasuchika
KFKen Fukumitsu
Ken Fukumitsu
TITakamichi Ishii
Takamichi Ishii
SOSatoshi Ogiso
Satoshi Ogiso
SUShinji Uemoto
Shinji Uemoto
Tissue decellularization produces a three‐dimensional scaffold that can be used to fabricate functional liver grafts following recellularization. Inappropriate cell distribution and clotting during blood perfusion hinder the practical use of recellularized livers. Here we aimed to establish a seeding method for the optimal distribution of parenchymal and endothelial cells, and to evaluate the effect of liver sinusoidal endothelial cells (LSECs) in the decellularized liver. Primary rat hepatocytes and LSECs were seeded into decellularized whole‐liver scaffolds via the biliary duct and portal vein, respectively. Biliary duct seeding provided appropriate hepatocyte distribution into the parenchymal space, and portal vein–seeded LSECs simultaneously lined the portal lumen, thereby maintaining function and morphology. Hepatocytes co‐seeded with LSECs retained their function compared with those seeded alone. Platelet deposition was significantly decreased and hepatocyte viability was maintained in the co‐seeded group after extracorporeal blood perfusion. In conclusion, our seeding method provided optimal cell distribution into the parenchyma and vasculature according to the three‐dimensional structure of the decellularized liver. LSECs maintained hepatic function, and supported hepatocyte viability under blood perfusion in the engineered liver graft owing to their antithrombogenicity. This recellularization procedure could help produce practical liver grafts with blood perfusion.

21 October 2016 in Scientific Reports
Verified
Journal Article
Open access
SOSatoshi Ogiso
Satoshi Ogiso
KYKentaro Yasuchika
Kentaro Yasuchika
KFKen Fukumitsu
Ken Fukumitsu
TITakamichi Ishii
Takamichi Ishii
HKHidenobu Kojima
Hidenobu Kojima
SUShinji Uemoto
Shinji Uemoto
A whole-organ regeneration approach, using a decellularised xenogeneic liver as a scaffold for the construction of a transplantable liver was recently reported. Deriving suitable scaffolds was the first step towards clinical application; however, effective recellularisation remains to be achieved. This report presents a strategy for the improvement of the recellularisation process, using novel cell-seeding technique and cell source. We evaluated recellularised liver grafts repopulated through the portal vein or the biliary duct with mice adult hepatocytes or E14.5 foetal hepatocytes. More than 80% of the cells seeded through the biliary tree entered the parenchyma beyond the ductule-lining matrix barrier and distributed throughout the liver lobule. In contrast, about 20% of the cells seeded through the portal tree entered the parenchyma. The gene expression levels of foetal hepatocyte albumin, glucose 6-phosphatase, transferrin, cytokeratin 19, and gamma-glutamyl transpeptidase were increased in three-dimensional cultures in the native liver-derived scaffolds, and the activation of liver detoxification enzymes and formation of biliary duct-like structures were supported. The metabolic functions of liver grafts recellularised with different cell types were similar. These results suggest that biliary tree cell-seeding approach is promising, and that liver progenitor cells represent a good cell source candidate.